Home
NICE Guidance
Published Guidance

The clinical effectiveness and cost effectiveness of infliximab for Crohn's disease

Technology appraisal guidance [TA40] Published date: 26 April 2002

Guidance

This guidance has been updated and replaced by NICE technology appraisal guidance 187.

About NICE
Into practice
News
Contact us
Leave feedback
Jobs

Newsletters and alerts
Blog
Twitter
YouTube
Facebook
LinkedIn

Explore

Guidance
Pathways
Standards and indicators
Evidence search
BNF
BNFC
Clinical knowledge summaries
Journals and databases

Reusing our content

Reuse information
NICE UK Open Content Licence

Get involved

Register as a stakeholder
Citizens council
Consultations
Fellows and scholars
Join a committee
Meetings in public
Student champions
Tenders
NICE and the public

Accessibility
Freedom of information
Syndication services
Glossary
Terms and conditions
Privacy notice

© NICE [year]. All rights reserved. Subject to Notice of rights.